Mon Sep 15 11:30:00 UTC 2025: Here’s a summary and a news article based on the provided text:

**Summary:**

aTyr Pharma (ATYR) stock saw a 7.5% increase on Friday, closing at $5.66, despite a decrease in trading volume. Recent analyst ratings are mixed, but generally positive, with a consensus rating of “Buy” and a price target of $23.25. The company recently reported earnings that missed expectations, and institutional investors have been adjusting their positions in the stock. aTyr Pharma is a biopharmaceutical company focused on developing medicines based on novel biological pathways. However, MarketBeat suggests other stocks may offer better investment opportunities.

**News Article:**

**aTyr Pharma Shares Jump Despite Earnings Miss, Analyst Ratings Mixed**

**SAN DIEGO, CA -** Shares of aTyr Pharma, Inc. (NASDAQ:ATYR) experienced a surge on Friday, climbing 7.5% to close at $5.66. The stock reached an intraday high of $5.63. However, trading volume was down 43% compared to the average, with 1,484,125 shares changing hands.

The positive price movement comes after aTyr Pharma reported its most recent quarterly earnings on August 7th, revealing a loss per share of ($0.22), which missed analyst expectations of ($0.18). Despite the earnings miss, several equity research firms have weighed in on the company recently. HC Wainwright reaffirmed a “Buy” rating with a $35 price target. Wells Fargo & Company raised its price target to $25, maintaining an “Overweight” rating. In contrast, Wall Street Zen downgraded aTyr Pharma to “Sell,” while Jefferies Financial Group increased its price target to $17, maintaining a “Buy” rating.

Overall, aTyr Pharma currently holds a consensus “Buy” rating with an average price target of $23.25, according to MarketBeat data. The company’s fundamentals show a market capitalization of $590.88 million, a price-to-earnings ratio of -7.54, and a beta of 1.01.

Institutional investors have also been adjusting their positions. Several firms, including Group One Trading LLC, California State Teachers Retirement System, and Two Sigma Advisers LP, initiated new positions in aTyr Pharma during recent quarters. Currently, hedge funds and other institutional investors hold 61.72% of the company’s stock.

aTyr Pharma is a biopharmaceutical company focused on developing medicines based on novel biological pathways, with a pipeline including ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1.

However, MarketBeat analysts suggest that other stocks may offer better investment opportunities than aTyr Pharma, despite its current “Buy” rating. They highlight five stocks they believe top analysts are recommending to clients. Investors are encouraged to conduct thorough research before making investment decisions.

Read More